Asthma Management Handbook
Close window

Table. Monoclonal antibody therapies currently available in Australia for severe asthma

Name Description Indication*

Dosage & route of

administration

Benralizumab (Fasenra)

Anti-IL-5 receptor

Humanised monoclonal antibody directed against IL-5 receptor Rα on surface of eosinophils and basophils

Add-on treatment for uncontrolled severe eosinophilic asthma in adults and adolescents aged ≥ 12 years

Prefilled syringe for SC injection

30 mg SC every 4 weeks for three injections then every 8 weeks
Mepolizumab (Nucala)

Anti-IL-5

Humanised monoclonal antibody directed against IL-5
Add-on treatment for uncontrolled severe eosinophilic asthma in adults and adolescents ≥12 years

Powder for SC injection in a single-use vial

100 mg SC every 4 weeks
Omalizumab (Xolair)

Anti-IgE

Humanised monoclonal antibody directed against IgE

Add-on treatment for uncontrolled severe allergic asthma in adults, adolescents and children aged ≥6 years

Prefilled syringe for SC injection

Dose calculated according to baseline IgE and body weight. Usual dose every 2–4 weeks (larger doses divided in 2 and administered every 2 weeks)

SC: subcutaneous

*Refer to TGA-approved indications and PBS criteria

Last reviewed version 2.0

Asset ID: 118